SIV Vpx Is Essential for Macrophage Infection but Not for Development of AIDS

Analysis of rhesus macaques infected with a vpx deletion mutant virus of simian immunodeficiency virus mac239 (SIVΔvpx) demonstrates that Vpx is essential for efficient monocyte/macrophage infection in vivo but is not necessary for development of AIDS. To compare myeloid-lineage cell infection in monkeys infected with SIVΔvpx compared to SIVmac239, we analyzed lymphoid and gastrointestinal tissues from SIVΔvpx-infected rhesus (n = 5), SIVmac239-infected rhesus with SIV encephalitis (7 SIV239E), those without encephalitis (4 SIV239noE), and other SIV mutant viruses with low viral loads (4 SIVΔnef, 2 SIVΔ3). SIV+ macrophages and the percentage of total SIV+ cells that were macrophages in spleen and lymph nodes were significantly lower in rhesus infected with SIVΔvpx (2.2%) compared to those infected with SIV239E (22.7%), SIV239noE (8.2%), and SIV mutant viruses (10.1%). In colon, SIVΔvpx monkeys had fewer SIV+ cells, no SIV+ macrophages, and lower percentage of SIV+ cells that were macrophages than the other 3 groups. Only 2 SIVΔvpx monkeys exhibited detectable virus in the colon. We demonstrate that Vpx is essential for efficient macrophage infection in vivo and that simian AIDS and death can occur in the absence of detectable macrophage infection.

[1]  N. Bhardwaj,et al.  HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. , 2014, AIDS research and human retroviruses.

[2]  S. Turville,et al.  Revising the Role of Myeloid cells in HIV Pathogenesis , 2013, Current HIV/AIDS Reports.

[3]  Kevin C. Olivieri,et al.  Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection , 2013, Retrovirology.

[4]  O. Schwartz,et al.  SAMHD1 Restricts HIV-1 Cell-to-Cell Transmission and Limits Immune Detection in Monocyte-Derived Dendritic Cells , 2012, Journal of Virology.

[5]  J. Hoxie,et al.  Loss of a Tyrosine-Dependent Trafficking Motif in the Simian Immunodeficiency Virus Envelope Cytoplasmic Tail Spares Mucosal CD4 Cells but Does Not Prevent Disease Progression , 2012, Journal of Virology.

[6]  R. König,et al.  SAMHD1 restricts HIV-1 infection in resting CD4+ T cells , 2012, Nature Medicine.

[7]  Y. Crow,et al.  SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells , 2012, Retrovirology.

[8]  Frederick Albert Matsen IV,et al.  The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. , 2012, Cell host & microbe.

[9]  Baek Kim,et al.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates , 2012, Nature Immunology.

[10]  B. Sobhian,et al.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.

[11]  M. Washburn,et al.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein , 2011, Nature.

[12]  B. Jia,et al.  Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. , 2011, Cell host & microbe.

[13]  R. Gonzalez,et al.  Myocarditis in CD8-Depleted SIV-Infected Rhesus Macaques after Short-Term Dual Therapy with Nucleoside and Nucleotide Reverse Transcriptase Inhibitors , 2010, PloS one.

[14]  F. Margottin-Goguet,et al.  Limelight on two HIV/SIV accessory proteins in macrophage infection: Is Vpx overshadowing Vpr? , 2010, Retrovirology.

[15]  Andrew D. Luster,et al.  Induction of Robust Cellular and Humoral Virus-Specific Adaptive Immune Responses in Human Immunodeficiency Virus-Infected Humanized BLT Mice , 2009, Journal of Virology.

[16]  S. Westmoreland,et al.  Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2 , 2009, PLoS pathogens.

[17]  K. Mansfield,et al.  Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet , 2009, Laboratory Investigation.

[18]  Rajnish Kaushik,et al.  Primate Lentiviral Vpx Commandeers DDB1 to Counteract a Macrophage Restriction , 2008, PLoS pathogens.

[19]  Smita Srivastava,et al.  Lentiviral Vpx Accessory Factor Targets VprBP/DCAF1 Substrate Adaptor for Cullin 4 E3 Ubiquitin Ligase to Enable Macrophage Infection , 2008, PLoS pathogens.

[20]  R. Desrosiers,et al.  Vaccine Protection by Live, Attenuated Simian Immunodeficiency Virus in the Absence of High-Titer Antibody Responses and High-Frequency Cellular Immune Responses Measurable in the Periphery , 2008, Journal of Virology.

[21]  J. Lifson,et al.  Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS , 2005, Journal of medical primatology.

[22]  H. McClure,et al.  Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb. , 2004, The American journal of pathology.

[23]  John P. Moore,et al.  Macrophage-Tropic Simian/Human Immunodeficiency VirusChimeras Use CXCR4, Not CCR5, for Infections of Rhesus MacaquePeripheral Blood Mononuclear Cells and AlveolarMacrophages , 2003, Journal of Virology.

[24]  R. Means,et al.  Determinants of Increased Replicative Capacity of Serially Passaged Simian Immunodeficiency Virus with nef Deleted in Rhesus Monkeys , 2003, Journal of Virology.

[25]  J. Lifson,et al.  SIVmac pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans , 2002, AIDS.

[26]  R. Desrosiers,et al.  Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in Rhesus monkeys. , 2001, The Journal of infectious diseases.

[27]  N Bischofberger,et al.  Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. McClure,et al.  Progressive infection in a subset of HIV-1-positive chimpanzees. , 2000, The Journal of infectious diseases.

[29]  J. Wakefield,et al.  Vpx is required for dissemination and pathogenesis of SIVSM PBj: Evidence of macrophage-dependent viral amplification , 1998, Nature Medicine.

[30]  R. Desrosiers,et al.  Identification of Highly Attenuated Mutants of Simian Immunodeficiency Virus , 1998, Journal of Virology.

[31]  A. Purvis,et al.  Complex evolutionary history of primate lentiviral vpr genes. , 1998, Virology.

[32]  V. Hirsch,et al.  Vpr of simian immunodeficiency virus of African green monkeys is required for replication in macaque macrophages and lymphocytes , 1997, Journal of virology.

[33]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[34]  P. Sharp,et al.  Nuclear import and cell cycle arrest functions of the HIV‐1 Vpr protein are encoded by two separate genes in HIV‐2/SIV(SM). , 1996, The EMBO journal.

[35]  P. Sharp,et al.  Gene acquisition in HIV and SIV , 1996, Nature.

[36]  D. Montefiori,et al.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus , 1996, Journal of virology.

[37]  R. Desrosiers,et al.  Copyright � 1995, American Society for Microbiology Progression to AIDS in the Absence of a Gene for vpr or vpx , 1994 .

[38]  A. Bergamini,et al.  Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding. , 1994, Blood.

[39]  R. Desrosiers,et al.  Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. , 1994, AIDS research and human retroviruses.

[40]  M. Tristem,et al.  Evolution of the primate lentiviruses: evidence from vpx and vpr. , 1992, The EMBO journal.

[41]  O. Bagasra,et al.  CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Simon,et al.  Pathologic features of SIV-induced disease and the association of macrophage infection with disease evolution. , 1992, AIDS research and human retroviruses.

[43]  R. Desrosiers,et al.  Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS. , 1991, The American journal of pathology.

[44]  R. Desrosiers,et al.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS , 1991, Cell.

[45]  N. Pedersen,et al.  Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. , 1990, Science.

[46]  A. Whetton,et al.  Granulocyte-macrophage colony-stimulating factor can stimulate macrophage proliferation via persistent activation of Na+/H+ antiport. Evidence for two distinct roles for Na+/H+ antiport activation. , 1990, The Biochemical journal.

[47]  G. Pari,et al.  Generation of a life-expanded rhesus monkey fibroblast cell line for the growth of rhesus rhadinovirus (RRV) , 2002, Archives of Virology.

[48]  L. Mucke,et al.  Pathogenesis of HIV-1 associated neurodegeneration. , 1996, Critical reviews in neurobiology.

[49]  E. Masliah,et al.  Measurement of CNS HIV burden and its association with neurologic damage. , 1994, Advances in neuroimmunology.

[50]  R. Desrosiers,et al.  Simian immunodeficiency virus—induced meningoencephalitis: Natural history and retrospective study , 1988, Annals of neurology.

[51]  R. Desrosiers,et al.  Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. , 2004, The American journal of pathology.